Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | AGXT | P21549 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7058069 | 0.83 | TSHR (0.47) | TSHRNAAAIDO1AGXTSMN1; SMN2 | |
| SCHEMBL18660678 | 0.77 | TSHR (0.52) | TSHRNAAAIDO1AGXTSMN1; SMN2 | |
| SCHEMBL265425 | 0.77 | TSHR (0.52) | TSHRNAAAIDO1AGXTSMN1; SMN2 | |
| SCHEMBL3438765 | 0.77 | TSHR (0.52) | TSHRNAAAIDO1AGXTSMN1; SMN2 | |
| SCHEMBL7794029 | 0.77 | TSHR (0.52) | TSHRNAAAIDO1AGXTSMN1; SMN2 | |
| SCHEMBL2351836 | 0.76 | HCAR2 (0.53) | TSHRSMN1; SMN2HTTHCAR2ALDH1A1 | |
| SCHEMBL19990182 | 0.76 | HCAR2 (0.53) | TSHRSMN1; SMN2HTTHCAR2ALDH1A1 | |
| SCHEMBL1428305 | 0.76 | TSHR (0.56) | TSHRNAAAIDO1SMN1; SMN2HTT | |
| SCHEMBL5254612 | 0.76 | GPR52 (0.50) | HCAR2 | |
| SCHEMBL146890 | 0.76 | GPR52 (0.50) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9416084-B2 | Method of producing ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2016-08-16 | — | — | US | claimed |
| US-12006311-B2 | Compounds for use in preventing or treating cancer | FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRONINSTITUT DE RECERCA (ES) | 2024-06-11 | — | — | US | disclosed |
| WO-2024083861-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | SELABTEC SCIENCES, SLU (ES) | 2024-04-25 | — | — | WO | disclosed |
| EP-4356909-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | Selabtec Sciences, SLU (ES) | 2024-04-24 | — | — | EP | disclosed |
| EP-3271468-B1 | DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES | LABORATORIO TECNICO DE SEGURIDAD Y ESTANDARIZACION SL (ES) | 2022-12-14 | — | — | EP | disclosed |
| US-20210230150-A1 | COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER | AMIRA THERAPEUTICS, S.L. (ES) | 2021-07-29 | — | — | US | disclosed |
| EP-3813832-A1 | COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (ES) | 2021-05-05 | — | — | EP | disclosed |
| EP-3640236-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2020-04-22 | — | — | EP | disclosed |
| EP-2595948-B1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LTD (IE) | 2019-09-04 | — | — | EP | disclosed |
| US-20180066295-A1 | DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES | LABORATORIO TECNICO DE SEGURIDAD Y ESTANDARIZACION, S.L.U. (ES) | 2018-03-08 | — | — | US | disclosed |
| US-20150315118-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2015-11-05 | — | — | US | disclosed |
| US-20150175622-A1 | 3-O-HETEROARYL-INGENOL | LEO LABORATORIES LIMITED (IE) | 2015-06-25 | — | — | US | disclosed |
| EP-2864290-A2 | 3-O-HETEROARYL-INGENOL | Leo Laboratories Limited (IE) | 2015-04-29 | — | — | EP | disclosed |
| CN-104411685-A | 3-o-heteroaryl-ingenol | LEO LAB LTD | 2015-03-11 | — | — | CN | disclosed |
| WO-2014191457-A1 | METHODS OF SYNTHESIS OF INGENOL AND INTERMEDIATES THEREOF | LEO LABORATORIES LIMITED (IE) | 2014-12-04 | — | — | WO | disclosed |
| US-8901356-B2 | Method of producing ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2014-12-02 | — | — | US | disclosed |
| WO-2014001215-A2 | 3-O-HETEROARYL-INGENOL | LEO LABORATORIES LIMITED (IE) | 2014-01-03 | — | — | WO | disclosed |
| US-20130177952-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | Hogberg, Thomas (DK) | 2013-07-11 | — | — | US | disclosed |
| EP-2595948-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012010172-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO PHARMA A/S (DK) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175622-A1 | 3-O-HETEROARYL-INGENOL | VDR, RXRA, PPARG | TSHR 793/4885NAAA 2428/4885IDO1 977/4885 |
| US-20150315118-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | PRKAG3, AMPD3, ERG28 | TSHR 2588/4885NAAA 1356/4885IDO1 2407/4885 |
| US-20130177952-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | PRKAG3, AMPD3, ERG28 | TSHR 2588/4885NAAA 1356/4885IDO1 2407/4885 |
| US-20210230150-A1 | COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER | UGT1A3, UGT1A1, UGT1A6 | TSHR 4736/4885NAAA 1615/4885IDO1 2846/4885 |
| US-12006311-B2 | Compounds for use in preventing or treating cancer | UGT1A3, UGT1A1, UGT1A6 | TSHR 4736/4885NAAA 1615/4885IDO1 2846/4885 |
| US-20180066295-A1 | DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES | ADA, CDA, DCTD | TSHR 1415/4885NAAA 112/4885IDO1 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.